Mobile

A Phase III, multicentre, double–blind, placebo controlled, cross over study to evaluate the safety and efficacy of subcutaneous bioresorbable implants of afamelanotide in the treatment of solar urtic...

Update Il y a 4 ans
Reference: EUCTR2008-002143-16

A Phase III, multicentre, double–blind, placebo controlled, cross over study to evaluate the safety and efficacy of subcutaneous bioresorbable implants of afamelanotide in the treatment of solar urticaria (SU)

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

Primary objective: To determine if afamelanotide increases the minimal urticarial dose (MUD) in subjects with solar urticaria (SU).

Inclusion criteria

  • Solar Urticaria (SU)

Links